Patents by Inventor Vaniambadi S. Kalyanaraman

Vaniambadi S. Kalyanaraman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5876732
    Abstract: A novel cell line chronically infected with HIV-2.sub.NIHZ virus secretes the precursor of the viral envelope proteins in extracellular medium. The cells grow well in serum-free medium which enables the concentration of the conditioned medium of the cells to be greatly increased (>100 fold). Such a concentration step is otherwise impossible to achieve if the cells are grown under conventional conditions using 10% fetal calf serum. A specific affinity procedure is provided to purify the gp160 protein from the concentrated conditioned medium of cultures of 100 liter batches using a mouse monoclonal antibody to the HIV-2 gp41 protein, which is a part of the gp160 protein. This purified HIV-2 gp160 reacts with high specificity and sensitivity with the anti viral antibodies of HIV-2 infected humans by several criteria such as i) ELISA, ii) western blot analysis, and iii) radioimmuno-precipitation of metabolically labeled gp160 from the same cell line.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: March 2, 1999
    Assignee: Akzo Nobel, N.V.
    Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman, Irene LaRue-Kalisz
  • Patent number: 5766844
    Abstract: A novel cell line chronically infected with HIV-2.sub.NIHZ virus secretes the precursor of the viral envelope proteins in extracellular medium. The cells grow well in serum-free medium which enables the concentration of the conditioned medium of the cells to be greatly increased (>100 fold). Such a concentration step is otherwise impossible to achieve if the cells are grown under conventional conditions using 10% fetal calf serum. A specific affinity procedure is provided to purify the gp160 protein from the concentrated conditioned medium of cultures of 100 liter batches using a mouse monoclonal antibody to the HIV-2 gp41 protein, which is a part of the gp160 protein. This purified HIV-2 gp160 reacts with high specificity and sensitivity with the anti viral antibodies of HIV-2 infected humans by several criteria such as i) ELISA, ii) western blot analysis, and iii) radioimmuno-precipitation of metabolically labeled gp160 from the same cell line.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: June 16, 1998
    Assignee: Akzo Nobel N.V.
    Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman, Irene LaRue-Kalisz
  • Patent number: 5736317
    Abstract: A novel cell line chronically infected with HIV-2.sub.NIHZ virus secretes the precursor of the viral envelope proteins in extracellular medium. The cells grow well in serum-free medium which enables the concentration of the conditioned medium of the cells to be greatly increased (>100 fold). Such a concentration step is otherwise impossible to achieve if the cells are grown under conventional conditions using 10% fetal calf serum. A specific affinity procedure is provided to purify the gp160 protein from the concentrated conditioned medium of cultures of 100 liter batches using a mouse monoclonal antibody to the HIV-2 gp41 protein, which is a part of the gp160 protein. This purified HIV-2 gp160 reacts with high specificity and sensitivity with the anti viral antibodies of HIV-2 infected humans by several criteria such as i) ELISA, ii) western blot analysis, and iii) radioimmunoprecipitation of metabolically labeled gp160 from the same cell line.
    Type: Grant
    Filed: March 7, 1995
    Date of Patent: April 7, 1998
    Assignee: Akzo Nobel N.V.
    Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman, Irene LaRue-Kalisz
  • Patent number: 5122468
    Abstract: Human Immunodeficiency Virus (HIV) glycoprotein gp160 is produced in its native form using a clone of HUT78 cells chronically infected with HTLV-III.sub.451, known as 6D5.sub.451, and grown in serum-free medium. gp160 is also produced in its native form using a clone of 6D5.sub.451 that contains no HTLV-III virus.
    Type: Grant
    Filed: December 14, 1989
    Date of Patent: June 16, 1992
    Assignee: Akzo N.V.
    Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman
  • Patent number: 5116740
    Abstract: Human Immunodeficiency Virus (HIV) glycoprotein gp160 is produced in its native form using a clone of HUT78 cells chronically infected with HTLV-III.sub.451, and grown in serum-free medium.
    Type: Grant
    Filed: June 7, 1989
    Date of Patent: May 26, 1992
    Assignee: Akzo N.V.
    Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman